13F Holdings
中文EN

EBS Emergent BioSolutions Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1367644 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-17.7%
TTM net income YoY-443.5%
TTM EPS YoY-475.0%
Revenue 3-yr CAGR-16.2%
Net income 3-yr CAGR—

Margins

Gross margin48.4%
Operating margin-27.7%
Net margin-40.2%
FCF margin29.0%
EBITDA margin-18.4%

Returns

ROE-58.2%
ROA-21.2%
ROIC (approx.)-17.3%
Asset turnover0.53x

Leverage & solvency

Liabilities / assets68.5%
Debt / equity1.62x
Current ratio4.58x
Interest coverage-3.96x

Cash quality & payout

Operating cash flow / net income-0.77x
Accruals ratio-37.5%
Payout ratio—
Capex / revenue1.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$742.90M$1.04B$1.05B$1.12B$1.77B
Cost of revenue$326.20M$681.30M$705.40M$693.10M$748.10M
Gross profit$416.70M$362.30M$317.60M$383.00M$891.30M
R&D expense$53.20M$70.70M$111.40M$188.30M$235.20M
SG&A expense$186.10M$308.00M$368.40M$339.50M$348.70M
Operating income$100.10M-$108.70M-$726.40M-$170.00M$341.40M
Interest expense$59.30M$71.00M$87.90M$37.30M$34.50M
Pretax income$82.80M-$142.90M-$731.20M-$219.00M$303.20M
Income tax$30.20M$47.70M$29.30M-$7.40M$83.70M
Net income$52.60M-$190.60M-$760.50M-$211.60M$219.50M
EBITDA$195.90M$100,000-$601.30M-$26.70M$465.20M
EPS (basic)0.98-3.60-14.85-4.224.10
EPS (diluted)0.93-3.60-14.85-4.224.06
Weighted avg. shares (diluted)56.70M53.00M51.20M50.10M54.10M
Balance sheet
Cash & equivalents$205.40M$105.60M$111.70M$642.60M$576.30M
Receivables$84.20M$154.50M$191.00M$159.20M$278.90M
Inventory$343.40M$311.70M$328.90M$350.70M$344.50M
Current assets$662.50M$598.70M$679.50M$1.21B$1.27B
PP&E, net$205.40M$270.60M$382.80M$817.60M$800.10M
Goodwill$0$0$0$218.20M$224.90M
Intangibles$436.50M$501.50M$566.60M$728.80M$604.60M
Total assets$1.32B$1.39B$1.82B$3.17B$2.96B
Current liabilities$132.20M$162.40M$651.30M$1.23B$374.00M
Short-term debt—$0$413.70M$957.30M$31.60M
Long-term debt$572.10M$663.70M$446.50M$448.50M$809.40M
Total debt$572.10M$663.70M$860.20M$1.41B$841.00M
Total liabilities$796.00M$906.90M$1.17B$1.78B$1.35B
Shareholders' equity$522.60M$482.80M$649.30M$1.39B$1.61B
Net debt$366.70M$558.10M$748.50M$763.20M$264.70M
Shares outstanding52.10M54.30M52.20M50.10M51.30M
Cash flow statement
Operating cash flow$170.60M$58.70M-$206.30M-$34.10M$320.20M
Capital expenditure$13.80M$22.90M$51.60M$115.80M$224.10M
Free cash flow$156.80M$35.80M-$257.90M-$149.90M$96.10M
Investing cash flow$69.40M$125.20M$212.30M-$381.30M-$224.10M
Financing cash flow-$136.60M-$190.00M-$535.70M$481.20M-$141.00M
Depreciation & amortization$95.80M$108.80M$125.10M$143.30M$123.80M
Stock-based compensation$16.20M$18.00M$23.10M$45.10M$42.40M
Share buybacks$24.90M$0$0$82.10M$106.00M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.